An early version of the Alzheimer’s drug Lekembi designed for home use has shown greater effectiveness than the hospital-based intravenous form in a recent study reported by the company Eisai.
Lekembi marks a breakthrough as the first medication able to meaningfully slow the progression of Alzheimer’s disease. Presently, it requires intravenous administration every two weeks in a clinical setting, a process that can pose barriers to broad adoption. In a new comparative study, scientists from Eisai evaluated outcomes in 72 patients receiving the home-use injectable formulation and 322 patients treated with the traditional intravenous version.
Over six months, the home-administered version reduced amyloid, a toxic protein linked to Alzheimer’s, by 14 percent more than the intravenous form. The incidence of key adverse events, including brain swelling and bleeding, remained similar between the two versions.
Even with the home-friendly version, Lekembi treatment requires periodic brain imaging to monitor amyloid and detect potential side effects. Nevertheless, the home-ready form is expected to expand accessibility by reducing the number of hospital visits and enabling more convenient monitoring while maintaining safety and efficacy standards.
Brain electrode before delivered A woman wanting to wash herself after cleaning the tray.